How to Buy Inhibikase Therapeutics Stock

Inhibikase Therapeutics Inc

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.

Inhibikase Therapeutics stock last closed at $2.31, up 5% from the previous day, and has increased 37.5% in one year. It has overperformed other stocks in the Biotechnology industry by 0.58 percentage points. Inhibikase Therapeutics stock is currently +73.68% from its 52-week low of $1.33, and -11.49% from its 52-week high of $2.61.

As of Sep 22, 2026, there are 139.54M IKT shares outstanding. The market cap of IKT is $322.33M. In the past 24 hours, 468,000 IKT shares were traded.

How to Buy Inhibikase Therapeutics Stock

Not sure how to invest in Inhibikase Therapeutics stock? Here's how.

  1. Figure out where to buy Inhibikase Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you choose where to buy Inhibikase Therapeutics stock.
  2. Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
  3. Deposit funds into your brokerage account: Choose your payment method and add your details.
  4. Research Inhibikase Therapeutics stock: The Inhibikase Therapeutics ticker symbol is IKT. Is Inhibikase Therapeutics stock a good investment? Should you buy shares of IKT? How do IKT's underlying business fundamentals look? Do top analysts think Inhibikase Therapeutics is a good buy? Why has IKT's stock price moved recently? (Hint: Our stock market research tools can help you understand if IKT is a good stock to buy).
  5. Execute your IKT purchase: Decide if you will purchase IKT shares at the current market price or use a limit order to purchase IKT shares at a specific price.
  6. Keep an eye on your IKT investment: Create a watchlist to monitor your investment in Inhibikase Therapeutics shares.

Step 1: Figure out where to buy Inhibikase Therapeutics stock

You need an online brokerage account to access the NASDAQ market and buy IKT stock.

A brokerage account enables you to buy and sell a variety of financial instruments, such as stocks, bonds, mutual funds, and ETFs.

Our recommended brokerage: eToro

Based on our analysis, eToro is the best brokerage. Here's why:

  • You can invest in stocks with zero commissions: Invest without commissions.
  • Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
  • Access to global markets: From Technology to Financial Services, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
  • Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
  • Security: eToro is a regulated and licensed brokerage platform.
  • Buy other financial assets: Such as ETFs and cryptocurrencies.

Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.

Open eToro Account
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.

Step 2: Create your brokerage account

Now that you've chosen the best brokerage, you'll need to fill out some personal details so you can buy IKT stock today.

How to Open a New Account on eToro

  1. Click here to get started.
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
  2. Enter your personal details to open your new brokerage account.
  1. Send your info by hitting the "Create Account" button.
  2. Get started with eToro today
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 3: Deposit funds into your brokerage account

Now that you have filled out your info on investing apps, your next step is to transfer the money for your investment:

Check out this video walkthrough if you need help transferring money into your new investment account.

Get started with eToro today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 4: Research Inhibikase Therapeutics stock

After you have chosen the best place to buy Inhibikase Therapeutics stock, it's absolutely critical to evaluate their stock prior to buying, so you actually understand the risk as well as the upside.

Inhibikase Therapeutics stock quick numbers

IKT Price
$2.31
1w %
0%
1y %
37.5%
5y %
-81.13%
P/E
-5.37x
P/B
2.1x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$60.64M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$322.33M
Next Earnings
Nov 13, 2026
Next Dividend
N/A

Inhibikase Therapeutics Fundamentals

WallStreetZen was designed to help everyday investors do more in-depth fundamental analysis quickly.

You can see all of the due diligence checks on IKT's stock page.

How is IKT stock valued?

Analysts use a variety of different financial metrics, analyses, models, and charts to gauge IKT's fair value.

Using relative valuations ratios:

  • IKT may be undervalued based on its P/B ratio of 2.1x, relative to Biotechnology industry P/B ratio of 5.33x

You can access more valuation analysis on IKT's stock here.

IKT Financial Health Summary

Pros:

  • IKT has $159.02M in cash and short term investments. This is enough to cover its annual cash burn of $42.61M.
  • IKT has a low debt to equity ratio of 0.07.
  • There are more short-term assets than long-term liabilities on the IKT balance sheet.
  • IKT has cash burn of 42612037. It has sufficient cash and short-term investments to cover this for at least one year.
  • There are more short-term assets than short-term liabilities on the IKT balance sheet.

Cons:

  • Total IKT debt is higher than 5 years ago, relative to shareholder equity.

You can dig deeper into what analysts are forecasting on the Inhibikase Therapeutics stock forecast page.

IKT Technical Indicators

SMA10
2.32
SMA20
2.39
SMA50
2.34
SMA100
2.08
SMA200
1.92
MACD
-0.02
MACD Signal
0
MACD Histogram
-0.02
RSI
47.05
Stochastic %K
14.11
Stochastic %D
12.6
StochRSI %K
14.08
StochRSI %D
4.69

How are IKT Revenues/Earnings doing?

Last year, IKT revenue was $0.00. Over the last five year, IKT's revenue has increased by -100% per year. This was slower than the Biotechnology industry average of 31.81%.

You can analyze IKT's earnings and revenue performance here.

What are IKT insiders up to?

Over the last 12 months, insiders at IKT have bought more shares than they have sold.

Dennis N. Berman, Director of IKT, was the latest IKT insider to buy. They bought $27,536.04 worth of IKT shares on Jul 30, 2026.

Get more info about who owns IKT shares here.

Does IKT stock generate passive income?

No, Inhibikase Therapeutics doesn't provide an income stream by paying out dividends.

What do other investors have to say about IKT?

One of the major reasons eToro is our favorite brokerage is because of its social trading community.

Click below to find out what other investors have to say.

Step 5: Execute your IKT purchase

You have two primary types of orders:

  • Market order: A market order is an order to buy or sell a stock at the best available price.
    Market orders are usually fine.
  • Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
    If you want to ensure you're buying or selling at a particular price, place a limit order.

Press the Open Trade button and your broker will execute the order.

If you require more assistance buying stocks on eToro, watch the helpful video below:

Open eToro Account

Step 6: Keep an eye on your IKT investment

Now that you own some IKT shares, you'll want to keep up with your shares.

Create a watchlist to track your IKT stock.

IKT Feed

How to Buy Stock in Inhibikase Therapeutics

To summarize, here are the 6 steps you need to take to buy Inhibikase Therapeutics stock right now:

  1. Figure out where to buy Inhibikase Therapeutics stock
  2. Create your brokerage account
  3. Deposit funds into your brokerage account
  4. Research Inhibikase Therapeutics stock
  5. Execute your IKT purchase
  6. Keep an eye on your IKT investment

If you require a place to buy stocks, eToro is our favorite venue.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

If you want to keep track of your investment in Inhibikase Therapeutics, add IKT to your watchlist by clicking the button below.

NASDAQ: IKT
$2.31+0.11 (+5%)
Updated Sep 22, 2026
Open eToro Account
Your capital is at risk.
NASDAQ: IKT
$2.31+0.11 (+5%)
Updated Sep 22, 2026
Open eToro Account
Your capital is at risk.

FAQ

How much does it cost to buy one Inhibikase Therapeutics share?

As of Sep 22, 2026, it costs $2.31 to buy one share of Inhibikase Therapeutics stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $1, you can buy 0.433 shares of IKT.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

What is the best way to buy Inhibikase Therapeutics stock?

One way to place an order for Inhibikase Therapeutics stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.